Evidence map›Paper›PMID 26559841›Full record

Observational studyJournal of virology2016

Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic.

Natalie N Kinloch, Daniel R MacMillan, Anh Q Le, Laura A Cotton, David R Bangsberg, Susan Buchbinder, Mary Carrington, Jonathan Fuchs, P Richard Harrigan, Beryl Koblin and 10 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 2 countries.

Natalie N KinlochFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
Daniel R MacMillanFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
Anh Q LeFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
Laura A CottonFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
David R BangsbergMassachusetts General Hospital, Boston, Massachusetts, USA Harvard Medical School, Cambridge, Massachusetts, USA.
Susan BuchbinderSan Francisco Department of Public Health, San Francisco, California, USA University of California, San Francisco, San Francisco, California, USA.
Mary CarringtonCancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA Ragon Institute of Massachusetts General Hospital, MIT, and Harvard University, Cambridge, Massachusetts, USA.
Jonathan FuchsSan Francisco Department of Public Health, San Francisco, California, USA University of California, San Francisco, San Francisco, California, USA.
P Richard HarriganBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Beryl KoblinNew York Blood Center, New York, New York, USA.
Margot KushelUniversity of California, San Francisco, San Francisco, California, USA.
Martin MarkowitzAaron Diamond AIDS Research Center, New York, New York, USA.
Kenneth MayerHarvard Medical School, Cambridge, Massachusetts, USA Fenway Community Health, Boston, Massachusetts, USA.
M J MilloyBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Martin T SchechterFaculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Theresa WagnerSan Francisco Department of Public Health, San Francisco, California, USA.
Bruce D WalkerRagon Institute of Massachusetts General Hospital, MIT, and Harvard University, Cambridge, Massachusetts, USA.
Jonathan M CarlsonMicrosoft Research, Seattle, Washington, USA.
Art F Y PoonFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada zbrumme@sfu.ca.
Simon Fraser University · CAUniversity of British Columbia · CAUniversity of California, San Francisco · USAIDS Vancouver · CAAaron Diamond AIDS Research Center · USFrederick National Laboratory for Cancer Research · USHarvard University · USMassachusetts General Hospital · USMicrosoft (United States) · USNew York Blood Center · USRagon Institute of MGH, MIT and Harvard · USSan Francisco Department of Public Health · US

Funding

San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
Effects of genetic polymorphism in MHC, KIR, and related loci on human diseaseZIABC010791 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$18.2M
CCR NIH HHS HHSN261200800001CCIHR HOP-115700CIHR MOP-93536Intramural NIH HHSNCI NIH HHS HHSN261200800001ENIAID NIH HHS UM1 AI069496
6 · The paper itself

Abstract

unlabelledHuman leukocyte antigen (HLA) class I-associated polymorphisms in HIV-1 that persist upon transmission to HLA-mismatched hosts may spread in the population as the epidemic progresses. Transmission of HIV-1 sequences containing such adaptations may undermine cellular immune responses to the incoming virus in future hosts. Building upon previous work, we investigated the extent of HLA-associated polymorphism accumulation in HIV-1 polymerase (Pol) through comparative analysis of linked HIV-1/HLA class I genotypes sampled during historic (1979 to 1989; n = 338) and modern (2001 to 2011; n = 278) eras from across North America (Vancouver, BC, Canada; Boston, MA; New York, NY; and San Francisco, CA). Phylogenies inferred from historic and modern HIV-1 Pol sequences were star-like in shape, with an inferred most recent common ancestor (epidemic founder virus) sequence nearly identical to the modern North American subtype B consensus sequence. Nevertheless, modern HIV-1 Pol sequences exhibited roughly 2-fold-higher patristic (tip-to-tip) genetic distances than historic sequences, with HLA pressures likely driving ongoing diversification. Moreover, the frequencies of published HLA-associated polymorphisms in individuals lacking the selecting HLA class I allele was on average ∼2.5-fold higher in the modern than in the historic era, supporting their spread in circulation, though some remained stable in frequency during this time. Notably, polymorphisms restricted by protective HLA alleles appear to be spreading to a greater relative extent than others, though these increases are generally of modest absolute magnitude. However, despite evidence of polymorphism spread, North American hosts generally remain at relatively low risk of acquiring an HIV-1 polymerase sequence substantially preadapted to their HLA profiles, even in the present era. IMPORTANCE: HLA class I-restricted cytotoxic T-lymphocyte (CTL) escape mutations in HIV-1 that persist upon transmission may accumulate in circulation over time, potentially undermining host antiviral immunity to the transmitted viral strain. We studied >600 experimentally collected HIV-1 polymerase sequences linked to host HLA information dating back to 1979, along with phylogenetically reconstructed HIV-1 sequences dating back to the virus' introduction into North America. Overall, our results support the gradual spread of many-though not all-HIV-1 polymerase immune escape mutations in circulation over time. This is consistent with recent observations from other global regions, though the extent of polymorphism accumulation in North America appears to be lower than in populations with high seroprevalence, older epidemics, and/or limited HLA diversity. Importantly, the risk of acquiring an HIV-1 polymerase sequence at transmission that is substantially preadapted to one's HLA profile remains relatively low in North America, even in the present era.

Indexed as

Adaptation, BiologicalGenetic VariationCohort StudiesEpidemicsGenotypeHistocompatibility Antigens Class IHIV-1HIV InfectionsHumansMaleNorth AmericaPhylogenypol Gene Products, Human Immunodeficiency VirusHistocompatibility Antigens Class Ipol Gene Products, Human Immunodeficiency Virus

Identifiers

PMID26559841
PMCPMC4719594
OpenAlexW2220568998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.